Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-08-02 Capital/Financing Update
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a binding term sheet for licensing) and includes references to exhibits such as the term sheet and a press release. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a significant corporate event related to licensing agreements. This fits the category of Capital/Financing Update (CAP), as it involves a material definitive agreement impacting the company's capital/licensing arrangements. The document length is about 4818 characters, which is consistent with a typical 8-K filing. Therefore, the best classification is CAP with high confidence.
2023-08-02 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 31, 2023, by ABVC BioPharma, Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement and the issuance of shares and pre-funded warrants. The document includes details about the transaction, placement agent fees, and references to exhibits such as the securities purchase agreement and warrants. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and related agreements, which aligns with updates on company financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not merely an announcement or certification, supporting a high confidence classification.
2023-07-31 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by ABVC BioPharma, Inc. It details the offering of common stock, pre-funded warrants, and placement agent warrants, including pricing, terms, and use of proceeds. The document is a formal offering document used to raise capital and is not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document itself. This fits the definition of a Capital/Financing Update, which covers updates on company fundraising and financing activities.
2023-07-31 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2023, reporting the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering of common stock and pre-funded warrants. It details the terms of the offering, the intended use of proceeds, and references attached exhibits including the purchase agreement and press release. The content focuses on a financing transaction and capital raising activity. There are no financial statements or earnings data presented, nor is this an announcement of voting results, management changes, or legal proceedings. The document is not a full annual or interim report, nor a call transcript or investor presentation. Given the focus on fundraising and capital structure changes, the appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not merely an announcement of a report publication or certification, so it is not RPA or RNS. Confidence is high due to clear identification of a securities purchase agreement and offering details.
2023-07-27 English
CURRENT REPORT
Share Issue/Capital Change Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a 1-for-10 reverse stock split, including details about the amendment to the Articles of Incorporation, the effective date, effects on shares, and related procedural information. There is no detailed financial data or comprehensive financial statements included, nor is it an earnings release or annual/interim report. The primary subject is a capital structure change (reverse stock split) and related corporate actions. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2023-07-24 English
FORM 8-K/A
Delisting Announcement Classification · 100% confidence The document is a Form 8-K/A filed with the SEC, which is a current report used to disclose material events. The content specifically discusses a notice of non-compliance with Nasdaq listing requirements and the potential for delisting if compliance is not achieved by a certain date. The key section is 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' This clearly indicates the document is an official notice related to delisting. The document length is 3815 characters, which is relatively short and focused on this specific event. Therefore, the appropriate classification is a Delisting Announcement (DLST).
2023-07-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.